ALHC (56) FRNM (36) TRUP (63) FTRE (35) ⌘ Pro Terminal →

Personalis Inc. (PSNL) — RQD Stock Rating Cockpit

$15.82 -0.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.77

Personalis Inc. (PSNL) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.70B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PSNL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PSNL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Personalis Inc. (NASDAQ: PSNL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $15.82 (-0.66% 1D, market cap $1.70B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PSNL ranks #626 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PSNL compare to ALHC and FRNM in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), PSNL carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 22.7%, and ROIC of -35.0%. By comparison, ALHC (Alignment Healthcare Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC 13.9%, cap $1.67B) and FRNM (Freenome Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -3.4%, cap $1.38B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PSNL?

▼

Per PSNL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527753), Personalis Inc. generated $69.6M in revenue (-17.7% YoY), -$81.3M in net income, and -$79.5M in free cash flow against $334.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.77 (-0.31%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PSNL)Realized 20D OHLCV Swing Band: ±4.1%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY PSNL SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (31% of score)

20D Institutional Volume Accumulation (±4.1% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)

Altman Z-Score 11.50 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$15.80+0.5% Next Q

Q2 (-2Q)

Grade E$15.88+0% Next Q

Q3 (-1Q)

Grade E$15.88-0.4% Next Q

Current

Grade D-$15.82-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PSNL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PSNL currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.29) and Max Pain ($16.61) forces dealer call-delta covering toward $19.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PSNL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PSNL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

11.50>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE78% OF RANGE

L: $5$15.82H: $19

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PSNL

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 22.7% gross margin and -4.67% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 11.50 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like PSNL

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PSNL)

✓Walkthrough of PSNL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PSNL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +168.14%▼ SUPPORT BREAKDOWN

2026-11-02O $16.00H $16.00L $15.82C $15.82VOL 749.3K

RES: $15.89SUP: $16.29SMA50: $16.29SMA200: $11.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PSNL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PSNL Butterfly Map → + Track PSNL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -17.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PSNL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PSNL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PSNL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PSNL)

Health Care Rank #626 of 1016 ⚔️ ALHC vs PSNL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PSNL vs. ALHC, FRNM, TRUP, FTRE)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Personalis Inc. (PSNL) ranks #626 by composite RQD confidence (36/100, grade D-) and #286 by equity capitalization ($1.70B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. TRUP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PSNL at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PSNL ACTIVE Personalis Inc.	D-	36/100	—	22.7%	-35.0%	-0.66%	$1.70B	Benchmark Subject
ALHC Alignment Healthcare Inc.	D+	56/100	—	—	13.9%	-9.80%	$1.67B	/alhc-vs-psnl →
FRNM Freenome Inc.	D-	36/100	—	—	-3.4%	-2.95%	$1.38B	/frnm-vs-psnl →
TRUP Trupanion Inc.	C	63/100	68.2x	16.1%	3.1%	-0.20%	$1.32B	/trup-vs-psnl →
FTRE Fortrea Holdings Inc.	D-	35/100	—	—	-35.0%	-7.97%	$2.20B	/ftre-vs-psnl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001527753

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Personalis Inc. (PSNL) reported GAAP revenue of $69.6M (-17.7% vs. FY2024 revenue of $84.6M , and -5.2% cumulative change since FY2023) , GAAP net income of -$81.3M, operating cash flow of -$74.9M, and free cash flow of -$79.5M (-69.9% YoY). On the balance sheet, PSNL closed FY2025 with $334.2M in total assets against $0 in total debt (Altman Z-Score: 11.50, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$69.6M	-$81.3M	-$74.9M	-$79.5M	$334.2M	—
FY2024 (FY)	2024-12-31	$84.6M	-$81.3M	-$45.1M	-$46.8M	$270.3M	—
FY2023 (FY)	2023-12-31	$73.5M	-$108.3M	-$56.3M	-$56.3M	—	—

3. PSNL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PSNL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PSNL compare to ALHC and FRNM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PSNL?

Where is PSNL trading relative to its 50-day, 200-day, and 52-week technical levels?

PSNL last traded at $15.82 (-0.66% on volume of 2,364,446 shares), positioning the stock -2.89% below its 50-day simple moving average ($16.29) and +39.75% above its 200-day simple moving average ($11.32). Across its 52-week range of $4.95 to $18.89, PSNL sits at the 78.0% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±4.1% ($15.17 to $16.47).

PSNL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PSNL stock right now?

Personalis Inc. (PSNL) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PSNL's 12-month price target and RQD AI Jury consensus?

PSNL's 12-month base price target is $14.25 (range $11.12 to $19.83), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PSNL RQD Cockpit PSNL 12M Forecast PSNL Earnings & Move PSNL Dividends & DRIP PSNL Insiders & 13F PSNL Whale Options PSNL Profit Sankey PSNL News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PSNL — Personalis Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:28:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PSNL scores 36 out of 100 with a letter grade of D- and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC of -35% and FCF yield of -4.67%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (beta of 1.0 and sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z of 11.5, Piotroski F of 3/9, Debt/Equity of 0.5). The weakest pillars are Insider Conviction and Fundamental Cash Engine, indicating that the cash-generation profile and insider signals provide little support for the thesis. The Forensic Balance Sheet score is comparatively stronger on the Altman Z reading, though the Piotroski score of 3/9 signals weak financial-quality tests. For a prospective investor, the rating frames the stock as one where negative free cash flow and negative returns on invested capital are the central considerations, with the bullish case resting mainly on the Altman Z reading and institutional positioning rather than on earnings or cash generation. This is an educational framing of the source data, not a recommendation.

Business

Personalis Inc. (PSNL) is a NASDAQ-listed issuer classified in the Health Care sector and the Medical Specialities industry, per the profile section. The source data does not describe its products, customers, or revenue model. The profile identifies the company's sector, industry, exchange, and market capitalization of $1.7B only. Revenue figures appear in the SEC financials, but the nature of the revenue streams is not specified in the source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$69.6M	$-88.1M	$-81.3M	N/A	$-79.5M	$124.2M	N/A
FY 2024	$84.6M	$-68.3M	$-81.3M	N/A	$-46.8M	$91.4M	N/A
FY 2023	$73.5M	$-109.9M	$-108.3M	N/A	$-56.3M	N/A	N/A

Per the SEC financials, revenue declined from $84.6M in FY 2024 to $69.6M in FY 2025, and operating losses were $-88.1M in FY 2025 against $-68.3M in FY 2024. The market data lists a gross margin of 22.7%, operating margin of -60%, and net margin of -60%, with ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 11.5 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash rose from $91.4M to $124.2M across the two most recent reported years despite negative free cash flow.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the items are as follows:

Catalyst (GREEN): A Yahoo Finance report headlined "Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years."
Market Wire (YELLOW): A Business Wire notice reporting an investigation following a $16.25 per share merger deal, with investors alerted to contact BFA Law.
Risk Watch (RED): A Stock Titan report stating no merger-related layoffs are anticipated as a Tempus takeover awaits closing.
Risk Watch (RED): An Investing.com UK report that BTIG downgraded the rating to neutral on acquisition outlook.
Market Wire (YELLOW): A Simply Wall St report on the company presenting at ESMO 2026 and whether the stock is overvalued.
Market Wire (YELLOW): A Stock Titan report on a cancer test that can show treatment-resistance mutations over time.

The news flow centers on a pending acquisition by Tempus, with the $16.25 per-share deal value referenced in the Business Wire item, and a neutral downgrade from BTIG tied to the acquisition outlook. The current price of 15.93 sits below the referenced $16.25 deal figure per the market data and news section. The Butterfly Supply-Chain Graph shows no supply-chain relationships and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations beyond the Health Care and Medical Specialities classification, and second-order bottlenecks are not available in source data. Investors should note that the pending acquisition referenced in the news flow is a concentrated event risk that the graph does not map.

Open Questions

What are the terms and expected closing timeline of the referenced Tempus acquisition, and what is the status of the referenced investigation?
What are the company's products, customers, and revenue sources that explain the decline from $84.6M to $69.6M?
What are the FY 2023 cash and debt balances, and what is the reported debt level given that debt is listed as N/A for all periods?
What is the reported EPS for any period, given that EPS is N/A across all filings?
What institutional, insider, or Congressional holdings and transactions underlie the RQD pillar scores for whale flow and insider conviction?

PSNL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Personalis Inc. (PSNL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PSNL Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 14h ago

Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years

Yahoo Finance report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 17h ago

PSNL Stock Notification: Personalis, Inc. is being Investigated after the $16.25 per share Merger Deal Announced – Investors are Alerted to Contact BFA Law

Business Wire report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 20h ago

Stock Titan report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com UK • 23h ago

BTIG downgrades Personalis stock rating to neutral on acquisition outlook By Investing.com

Investing.com UK report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Personalis (PSNL) Presents At ESMO 2026, Is The Stock Now Overvalued?

Simply Wall St report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A cancer test report can now show mutations tied to treatment resistance over time.

Stock Titan report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Personalis Inc. (PSNL) Slips to $15.65 as Shares Pull Back Within Recent Range - Relative Volume

https://www.siam.in/ report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

What Personalis (PSNL)'s Variant Tracking Launch Means For Shareholders

Simply Wall St report covering Personalis Inc. (PSNL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PSNL Bull vs. Bear Conversation Board — What's Your Call at $15.82?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PSNL 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $14.02 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PSNL (D- • RQD 36/100) a Buy at $15.93?

Welcome to the PSNL (Personalis Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.27 (-23.0%)

Spot @ $15.93

Pump the brakes on PSNL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PSNL, but look at what you are paying: current EV/EBITDA multiples with 22.7% gross margins. Unless Personalis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $19.28 (+21.0%)

Spot @ $15.93

PSNL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PSNL, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $15.93 (52-wk range $4.95 - $18.89), any beat on forward guidance forces shorts and underweight funds to chase.